Palvella Therapeutics (PVLA) Net Equity Issued and Repurchased (2013 - 2026)

Palvella Therapeutics (PVLA) has reported Net Equity Issued and Repurchased for 8 consecutive years, with $230.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Equity Issued and Repurchased changed N/A year-over-year to $230.0 million; the TTM figure through Mar 2026 stood at $230.0 million (changed N/A YoY), while the FY2023 annual figure was $19.7 million, up 185.02% from the prior year.
• Net Equity Issued and Repurchased rose to $230.0 million in Q1 2026 per PVLA's latest filing, from $19.7 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $230.0 million in Q1 2026 and bottomed at $167000.0 in Q2 2022.
• Historically, Net Equity Issued and Repurchased has averaged $51.3 million across 3 years, with a median of $6.5 million in 2022.
• Annual changes were most pronounced in 2022 — Net Equity Issued and Repurchased tumbled 98.68% — and 2023, when it surged 11713.77%.
• Palvella Therapeutics' Net Equity Issued and Repurchased stood at $282000.0 in 2022, then soared by 6896.1% to $19.7 million in 2023, then surged by 1065.8% to $230.0 million in 2026.
• Business Quant data shows PVLA's Net Equity Issued and Repurchased at $230.0 million in Q1 2026, $19.7 million in Q2 2023, and $282000.0 in Q3 2022.